An international study verified in November 2011 is recruiting about 300 fibromyalgia patients for a trial of experimental time-release pregabalin (brand name Lyrica®). Though the trial is placebo controlled, randomized and double-blinded, all of the patients will receive pregabalin at some point in the study, and all will receive placebo at some point.
The five-month Phase 3 trial will measure the once-a-day delivery mode’s time to loss of therapeutic pain relief at different doses from 165mg to 495 mg, and will require participants to keep daily pain, tiredness, and sleep diaries.
Participants must be at least age 18, with no upper age limit. The 52 clinics recruiting for the trial are located in:
• 20 states in the US,
• Across Canada (British Columbia, Manitoba, New Brunswick, Ontario, and Quebec),
• Across India,
• And at 4 clinics in Taiwan.
For more information about the trial and for contact information/links, see ClinicalTrials.gov trial listing # NCT01271933.